ClinicalTrials.gg
CompletedNCT01870362Updated Jul 23, 2014

Efficacy of a Probiotic Lozenge (Inersan) in Patients With Chronic Periodontitis

A Phase 3 interventional study of Probiotic (Inersan) and Placebo in Chronic Periodontitis, sponsored by CD Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-07-23.

Sponsored by CD Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Chronic Periodontitis with a site in India — 2 open to participants now, 3 under way, none of them phase 3. Chronic Periodontitis · India.

Enrollment
40th of 46
28 · median 53
Started
2013
with 3 others
Phase 3
8 of 53
none open now
Registered
1st of 53
by date
Lead sponsor
3 of 53
CD Pharma India Pvt. Ltd.

Among the 53 studies in Chronic Periodontitis with a site in India, this one is the 40th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2013, is one of 8 in phase 3, and was the 1st registered.

Chronic Periodontitis

377 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.

Browse Chronic Periodontitis studies →

Open to participants now

2 of the 53 studies in Chronic Periodontitis with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 25 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Chronic Periodontitis with a site in India, or all of them as a file.
02

Study summary

Periodontal disease is a major cause of tooth loss in humans and is one of the most prevalent diseases associated with bone loss. Following bacterial colonization, the gingiva becomes inflamed leading, in some cases, to the destruction of the alveolar bone. Periodontitis has two distinct but interconnected etiologic components, periodontopathic bacteria and host-mediated connective tissue-destructive responses to the causative bacteria and their metabolic products.

A few studies have revealed that probiotic Lactobacillus strains were useful in reducing gingival inflammation and the number of black-pigmented rods, including Porphyromonas gingivalis (Pg), in the saliva and sub-gingival plaque. Concerning periodontal conditions, its shown that application of beneficial bacteria, as an adjunct to scaling and root planing (SRP), can inhibit re-colonization of pathogens in periodontal pockets and reduce bleeding on probing.

The aim of the present study is to evaluate the improvement of periodontal health with probiotic (Inersan) lozenges, used as an adjunct to scaling and root planing [SRP].

03

Conditions studied

  • Chronic Periodontitis

Browse trials for

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of both sexes
  • Patients in the age group of 25-60 years
  • Subjects with mild to moderate chronic periodontitis, as defined by probing pocket depths 5-7mm in > 30 % of the probing sites
  • The subjects should have at least 16 remaining natural teeth (minimum of at least 4 teeth per quadrant)
  • Subjects in good general health

Exclusion criteria

Exclusion Criteria:

  • No antibiotic therapy in the past 2 months
  • Medically compromised patients
  • Subjects who are pregnant/ lactating
  • Smokers and/or alcoholics.
  • Those who had undergone any dental surgical or non-surgical therapy within 6 months prior to the start of the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Probiotic (Inersan) Arm

    Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2

    Drug: Probiotic (Inersan)

  • Placebo comparator
    Placebo Arm

    Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).

    Drug: Placebo

Interventions

  • Also known as: Inersan contains not less than 1 billion CFU of Lactobacillus brevis CD2

  • DrugPlacebo

    Also known as: Placebo contains all excipients except the active constituent (Lactobacillus brevis CD2)

06

What researchers measure

Primary outcomes

  1. Improvement in periodontal indices

    Improvement in Periodontal indices, namely, plaque index \[PI\], Gingival index \[GI\], Gingival bleeding index \[GBI\], probing pocket depth \[PPD\] and clinical attachment levels \[CAL\] in both groups

    Time frame: 6 weeks, 12 weeks

Secondary outcomes

  1. Microbiological indices

    Changes in pathogen (Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), and Prevotella intermedia) levels

    Time frame: 6 weeks, 12 weeks

07

Study locations

1 site
  • Mahatma Gandhi Post Graduate Institute of Dental Sciences (MGPGI)
    Puducherry, 605006, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2013
First posted
Jun 6, 2013
Start
Jun 2013
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Jul 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01870362
Lead sponsor
CD Pharma India Pvt. Ltd.
Collaborators
Mahatma Gandhi Post-Graduate Institute of Dental Sciences
Responsible party
Sponsor
First posted
Jun 6, 2013
Start date
Jun 2013
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Jul 23, 2014

Study contacts

Grace T Paul, MBBS, MDS
principal investigator · Mahatma Gandhi Post- Graduate Institute of Dental Sciences, Pondicherry

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion